CD19 and systemic lupus erythematosus: In a post-hoc analysis of three clinical trials of belimumab in SLE, the results showed flared patients who received standard therapy, and displayed less prominent early decreases in CD19+CD20−CD138+ long-lived plasma cells (−11.3% versus −29.2%; p = 0.019).